Published in Oncology Business Week, November 14th, 2004
The Thousand Oaks, California-based company reported a third-quarter profit of $236 million, or 18 cents a share. That's a 61% decrease compared to $612 million, or 46 cents a share, for the same period a year ago.
Earnings decreased primarily because of a $554 million write-off related to Amgen's purchase of biotechnology company Tularik Inc.
Amgen said if not for the Tularik acquisition and other special expenses, its earnings would have been $839...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.